FBL Avocats advises Axoltis Pharma on its €18 million Series A funding round.

FBL Avocats advisesAxoltis Pharma on its €18 million Series A funding round.

We are extremely proud to have supported AXOLTIS PHARMA in its €18 million fundraising, a strategic operation for a company whose drug candidate is currently in Phase 2 clinical trials for patients with amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease.

For this transaction, our Private Equity & Venture Capital team consisted of Julien Gruys (Partner), Agathe WOLF (Associate) and Diane Koëhl (Legal Counsel).

Thank you to Yann GODFRIN, Ph.D., Jérémy Caïmi and the AXOLTIS PHARMA teams for their trust.

We wish them great success in the next stages of development for the project led by AXOLTIS PHARMA!